Read About Ocrevus and Relapsing Multiple Sclerosis

Multiple sclerosis is a condition in which the immune system can damage the protective covering of nerves in the central nervous system. Relapsing forms of MS can involve periods of new or worsening symptoms followed by periods of improvement. Ocrevus, whose active ingredient is ocrelizumab, is a CD20 directed antibody used for relapsing forms of MS and primary progressive MS in adults. The current United States prescribing information lists clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease among its relapsing MS indications.

How Ocrevus Works in Relapsing Multiple Sclerosis

Ocrevus works by targeting CD20 positive B cells, a type of immune cell involved in the body's immune response. Reducing these cells can help decrease immune activity that contributes to inflammation and damage associated with MS.

For people receiving Ocrevus, treatment involves medical supervision and appropriate monitoring. Important considerations include:

• Ocrevus is administered by a healthcare professional.
• Treatment requires an initial dosing schedule followed by maintenance treatment at regular intervals.
• Screening for hepatitis B virus is recommended before starting treatment.
• Quantitative serum immunoglobulin levels should be assessed before treatment.
• Patients may be monitored for infusion related reactions during and after administration.

The goal of disease modifying treatment is to reduce disease activity and help manage the progression of relapsing MS. Individual treatment choices depend on factors such as disease activity, medical history, other medications, and healthcare professional recommendations.

Safety Considerations and Monitoring During Treatment

Like other medicines that affect immune system activity, Ocrevus can have risks that need to be considered before and during treatment. Infusion reactions may occur, and infections are an important safety consideration because treatment affects certain immune cells.

Healthcare professionals may consider several factors when evaluating whether Ocrevus is appropriate:

• A history of infections or conditions affecting the immune system.
• Hepatitis B screening results before treatment.
• Immunoglobulin levels and relevant medical history.
• Previous or current treatments that may affect immune function.
• Any symptoms that develop during or after an infusion.

The FDA prescribing information identifies active hepatitis B infection as a contraindication and recommends specialist consultation in certain patients with evidence of previous or current hepatitis B infection.

Ocrevus is one option within the broader range of disease modifying therapies used for multiple sclerosis. Patients should discuss expected benefits, possible risks, monitoring requirements, and alternative treatments with their healthcare professional rather than making treatment decisions based solely on general information.

Ocrevus is an established disease modifying therapy for relapsing forms of multiple sclerosis in adults. Understanding how it works, its administration, screening requirements, and potential safety considerations can help patients have informed discussions with their healthcare team. This information is educational only and is not intended to replace professional medical advice.